Company: GNMSF
Filing Date: 2025-09-29
Form Type: SC TO-C
Source: 0000947871-25-000868
Chunk: 4

Company: GENMAB A/S
Filing Date: 2025-09-29
Form: SC TO-C
Chunk 4
---
 States or worldwide on
Genmab’s and/or the Company’s business, financial condition and results of operations, as well the response thereto by
each company’s management; and other business effects, including the effects of industry, market, economic, political or
regulatory conditions. Also, actual results or performance of Genmab and the Company may differ materially from any future results
or performance expressed or implied by such statements for a number of additional reasons as described in Genmab’s and the
Company’s respective filings with the SEC, including those included in Genmab’s most recent Annual Report on Form 20-F,
which is available at www.genmab.com and www.sec.gov and those included in the Company’s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2025, which is available at https://ir.merus.nl/ and www.sec.gov. Neither Genmab nor the Company
undertakes any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements
to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

<div align='center'>***</div>

| Item 12. | Exhibits. |

| (a)(5)(a) | Company Announcement, dated September 29, 2025: Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model |

| (a)(5)(b) | Genmab investor call slides, dated September 29, 2025 |

| (a)(5)(c) | Social Media posts of Genmab and Jan G.J. van de Winkel, President and Chief Executive Officer of Genmab, dated September 29, 2025 |

| (a)(5)(d) | Investor Relations call transcript, dated September 29, 2025 |